Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

0RD1

Camurus Ab (0RD1)

Camurus Ab
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:0RD1
日付受信時刻ニュースソース見出しコード企業名
2023/07/1714 : 40PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
2023/07/1714 : 36PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
2023/05/2412 : 25PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
2023/05/2412 : 17PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
2021/12/1607 : 15PR Newswire (US)Braeburn receives new Complete Response Letter for Brixadi in the USLSE:0RD1Camurus Ab
2021/09/1618 : 38PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
2021/09/1618 : 37PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
2021/06/2701 : 09PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
2021/06/2701 : 02PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
2021/06/1607 : 12PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
2021/06/1607 : 05PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
2021/05/1100 : 22PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
2021/05/1100 : 21PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
2021/05/0315 : 42PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
2021/05/0315 : 40PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
2021/03/2622 : 33PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
2021/03/2622 : 32PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
2020/12/1816 : 27PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
2020/12/1816 : 26PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
2020/06/2421 : 38PR Newswire (US)Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...LSE:0RD1Camurus Ab
2020/06/2323 : 39PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
2020/06/2323 : 33PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
2020/06/0206 : 55PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
2020/06/0206 : 52PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
2020/05/1500 : 24PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
2020/05/1500 : 22PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
2020/05/0720 : 18PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
2020/05/0720 : 17PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
2020/04/0215 : 37PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
2020/04/0215 : 32PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
 Showing the most relevant articles for your search:LSE:0RD1